Eli Lilly’s Breakthrough Obesity Pill Achieves 12% Weight Loss in Key Late-Stage Trial: A Game Changer for Weight Management

Eli Lilly recently shared exciting news about its new weight loss pill. In a late-stage trial, the highest dose helped patients shed nearly 12% of their body weight, which is about 27 pounds over 72 weeks. After this announcement, the company’s shares dropped more than 12% in premarket trading, as some analysts had expected even higher results.

This pill, called orforglipron, aims to enter the booming market for GLP-1 medications, which include popular options like Novo Nordisk’s Wegovy. Dr. Jaime Almandoz, a medical director at UT Southwestern, found the results promising, especially for patients who may be wary of injections. He believes oral medications could greatly change obesity treatment, making it more accessible to those who dislike needles.

According to Eli Lilly, over 59% of participants lost at least 10% of their weight during the trial, and more than 39% achieved a loss of 15% or more. However, there are concerns regarding side effects. About 10.3% of patients stopped taking orforglipron due to side effects like nausea and vomiting. This percentage is higher compared to other existing GLP-1 options, where discontinuation rates for side effects hover around 7%.

Dr. Caroline Apovian from Brigham and Women’s Hospital cautions that while excitement surrounds this new pill, many patients dropped out of the trial for various reasons, not just side effects. Experts like Dr. Amy Sheer believe that the pill could be more cost-effective than existing injectables since many insurers currently don’t cover GLP-1 drugs for obesity, which can cost around $1,000 monthly without insurance.

As Eli Lilly prepares to submit data to regulators by the year’s end and plans to launch the pill in 2026, there’s a significant potential market to tap into. Custer, president of Lilly’s Cardiometabolic Health division, noted that about 170 million people may need treatments like these. Oral medications such as orforglipron could ease supply chain issues related to injections, making them available to more patients.

The pharmaceutical landscape is rapidly evolving. Experts expect the market for GLP-1 drugs to exceed $150 billion by the early 2030s, with oral alternatives potentially capturing a large share of that growth.

In summary, Eli Lilly’s new pill shows great promise, but it also raises questions about tolerability and insurance coverage. As researchers continue to study its efficacy and safety, it’s clear this development could reshape obesity treatment in the coming years.

For more in-depth information, you can check out recent findings on GLP-1 medications from reputable sources like the New England Journal of Medicine.

Source link

Breaking News: Business,Health care industry,Pharmaceuticals,Biotech and Pharmaceuticals,Biotechnology,Business,Eli Lilly and Co,Novo Nordisk A/S,Novo Nordisk A/S,business news